N4-Benzoylcytosine CAS 26661-13-2 Purity ≥99.0% Sofosbuvir Intermediate Factory

Name: N4-Benzoylcytosine

CAS: 26661-13-2

Appearance: White or Off-White Powder

Purity: ≥99.0% (HPLC) 

Intermediate of Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV)

High Quality, Commercial Production 

Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Commercial Supply Sofosbuvir and Related Intermediates: Sofosbuvir CAS: 1190307-88-0 N4-Benzoylcytosine CAS: 26661-13-2 triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane CAS: 21382-82-1 Pentafluorophenol CAS: 771-61-9 N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8
Item Specifications
Appearance White or Off-White Powder
Identification HPLC
Purity / Analysis Method ≥99.0% (HPLC)
Moisture (K.F) ≤0.50%
Loss on Drying ≤0.50%
Residue on Ignition ≤0.50%
Cytosine ≤0.50%
Heavy Metals  ≤20ppm
Test Standard Enterprise Standard
Upstream Product Cytosine CAS: 71-30-7
Usage Intermediate of Sofosbuvir (CAS: 1190307-88-0)  

Description:

Specifications:

Package & Storage:

Name N4-Benzoylcytosine
CAS Number 26661-13-2
CAT Number RF-PI178
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H9N3O2
Molecular Weight 215.21
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Manufacturer with High Purity and Stable Quality Commercial Supply Sofosbuvir (CAS: 1190307-88-0) and Related Intermediates:  Sofosbuvir CAS: 1190307-88-0  N4-Benzoylcytosine CAS: 26661-13-2 triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane CAS: 21382-82-1  Pentafluorophenol CAS: 771-61-9  N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8 Sofosbuvir (CAS: 1190307-88-0) is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. 

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours